Pimecrolimus: Me-too: Too many risks, not beneficial enough in atopic dermatitis

Prescrire International

Volumn 13, Issue 74, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; EXCIPIENT; KETOCONAZOLE; PIMECROLIMUS; PROPYLENE GLYCOL; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CHILD CARE; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DERMATITIS; DESQUAMATION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG WITHDRAWAL; ERYTHEMA; EYE INFECTION; FOLLOW UP; FRANCE; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; MEDICAL ASSESSMENT; META ANALYSIS; MOUSE; NONHUMAN; NOSE INFECTION; OTITIS; PAIN; PHARYNGITIS; PHOTOTHERAPY; PREGNANCY; PROTECTIVE CLOTHING; RAT; RHINOPHARYNGITIS; RISK ASSESSMENT; SCARLET FEVER; SKIN ATROPHY; SKIN CANCER; SKIN EDEMA; SKIN INFECTION; SKIN INFLAMMATION; SOFT TISSUE INFECTION; SPONTANEOUS ABORTION; SYMPTOM; SYSTEMATIC REVIEW; THYROID CANCER; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VERRUCA VULGARIS; WART VIRUS; ADULT; CHILD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; INFANT; INTRADERMAL DRUG ADMINISTRATION; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG APPROVAL; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MULTICENTER STUDIES; RECURRENCE; TACROLIMUS; TREATMENT OUTCOME;

EID: 16544388407     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prescrire Editorial Staff "Tacrolimus ointment - too many unknowns for use in atopic dermatitis" Prescrire Int 2003; 12 (71): 86-89.
2. Bornhövd E et al. "Macrolactam immunomodulators for topical treatment of inflammatory skin diseases" J Am Acad Dermatol 2001; 45 (5): 736-743.
3. O'Neil MJ et al. "The Merck index" 13th ed, Merck, Whitehouse Station 2001: 1331 + 1611.
4. Agence française de sécurité sanitaire des produits de santé "Résumé des caractéristiques du produit - Elidel° 1 % crème" 3 March 2003: 10 pages.
5. Food and Drug Administration - Center for drug evaluation and research "Application number: 21 - 302. Medical review" June 2001: 119 pages, and Statistical review May 2001: 56 pages.
6. Novartis Pharma: Elidel" (pimecrolimus). Expert report: 61 pages.
7. Eichenfield LF et al. "Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents" J Am Acad Dermatol 2002; 46 (4): 495-504.
8. Ho VC et al. "Safety and efficacy of nonsteroid pimecrolimus cream 1 % in the treatment of atopic dermatitis in infants" J Pediatrics 2003; 142 (2): 155-162.
9. Van Leent EJM et al. "Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis" Arch Dermatol 1998; 134: 805-809.
10. Luger T et al. "SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis" Br J Dermatol 2001; 144: 788-794.
11. Wahn U et al. "Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children" Pediatrics 2002; 110 (1): 1-8.
12. Kapp A et al. "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug" J Allergy Clin Immunol 2002; 110 (2): 277-284.
13. Meurer M et al. "Long-term efficacy and safety of primecrolimus cream 1% in adults with moderate atopic dermatitis" Dermatology 2004; 208: 365-372.
14. Van Leent EJM et al. "Low systemic exposure after repeated topical application of pimecrolimus (Elidel°, SDZ ASM 981) in patients with atopic dermatitis" Dermatology 2002; 204: 63-68.
15. Harper J et al. "First experience of topical SDZ ASM 981 in children with atopic dermatitis" Br J Dermatol 2001; 144 (4): 781-787.
16. Queille-Roussel C et al. "The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study" Br J Dermatol 2001; 144 (3): 507-513.
17. "Severe applicaions site reactions with pimecrolimus (Elidel)" 17th Medicines Adverse Reactions Committee Meeting 10 March 2004; abstr.: 1 page.
18. Pitts MR "Post-marketing AE reports of topical calcineurin inhibitors" Pediatric Advisory Subcommittee of the Anti-infective Drugs Advisory Committee, Food and Drug Administration, 30 October 2003: 1-13.
19. Meurer M et al. "Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study" Dermatology 2002; 205: 271-277.